These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15544998)

  • 1. [MRI evaluation of primary chemotherapy response in breast cancer].
    Vénat-Bouvet L; Desfougères M; Aubard Y; Mollard J; Fermeaux V; Genet D; Labourey JL; Martin J; Lebrun-Ly V; Maubon A; Tubiana-Mathieu N
    Bull Cancer; 2004 Sep; 91(9):721-8. PubMed ID: 15544998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.
    Peintinger F; Kuerer HM; McGuire SE; Bassett R; Pusztai L; Symmans WF
    Br J Surg; 2008 Apr; 95(4):433-7. PubMed ID: 18161887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients.
    Nagashima T; Sakakibara M; Nakamura R; Arai M; Kadowaki M; Kazama T; Nakatani Y; Koda K; Miyazaki M
    Eur J Radiol; 2006 Nov; 60(2):270-4. PubMed ID: 16926079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
    Guarneri V; Pecchi A; Piacentini F; Barbieri E; Dieci MV; Ficarra G; Tazzioli G; Frassoldati A; Battista R; Canossi B; Mauri C; D'Amico R; Conte P; Torricelli P
    Ann Surg Oncol; 2011 Aug; 18(8):2150-7. PubMed ID: 21301969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study.
    Bollet MA; Thibault F; Bouillon K; Meunier M; Sigal-Zafrani B; Savignoni A; Diéras V; Nos C; Salmon R; Fourquet A;
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):13-8. PubMed ID: 17449193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
    Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
    Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS; Apple SK
    Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
    Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
    Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Chen X; Moore MO; Lehman CD; Mankoff DA; Lawton TJ; Peacock S; Schubert EK; Livingston RB
    Acad Radiol; 2004 Oct; 11(10):1115-24. PubMed ID: 15530804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
    Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
    J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
    Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of re-excision among women undergoing breast-conserving surgery for cancer.
    Waljee JF; Hu ES; Newman LA; Alderman AK
    Ann Surg Oncol; 2008 May; 15(5):1297-303. PubMed ID: 18259820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
    Apple SK; Suthar F
    Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
    Rosen EL; Blackwell KL; Baker JA; Soo MS; Bentley RC; Yu D; Samulski TV; Dewhirst MW
    AJR Am J Roentgenol; 2003 Nov; 181(5):1275-82. PubMed ID: 14573420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of diffusion weighted imaging (DWI) in evaluating early response to neoadjuvant chemotherapy in locally advanced breast cancer].
    Wang XH; Peng WJ; Tan HN; Xin C; Gu YJ; Tang F; Mao J
    Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):377-81. PubMed ID: 20723438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients.
    Choi HK; Cho N; Moon WK; Im SA; Han W; Noh DY
    Eur J Radiol; 2012 Apr; 81(4):737-43. PubMed ID: 21300498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of reexcision for breast cancer after magnetic resonance imaging-guided bracket wire localization.
    Wallace AM; Daniel BL; Jeffrey SS; Birdwell RL; Nowels KW; Dirbas FM; Schraedley-Desmond P; Ikeda DM
    J Am Coll Surg; 2005 Apr; 200(4):527-37. PubMed ID: 15804466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.